Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Laekna Therapeutics
Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials
Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...
Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study
Laekna, a Sino-US biotech firm, has announced the commencement of a subcutaneous dosing cohort within...
Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...
Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...
Laekna’s ActRIIA Monoclonal Antibody LAE102 Gets Green Light from China’s CDE for Obesity Treatment
Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the...
Laekna’s Anti-ActRIIA Antibody LAE102 Clears FDA Hurdle for Obesity Treatment Trial
Sino-American biotech firm Laekna has announced that it has received clinical trial approval from the...
Sino-US Laekna’s LAE102 Clinical Trial Filing Accepted for Review in Obesity and Metabolic Disorders
Sino-US Laekna (HKG: 2105) has announced that its clinical trial application for LAE102, an antibody...
Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer
Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...
Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion
Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO)...
Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC
Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with...
Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer
China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...
Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...